Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Yamo’s L1-79 misses statistical significance
June 2019
SHARING OPTIONS:

NEW YORK—May saw Yamo Pharmaceuticals LLC share results from its Phase 2 study of L1-79 for the treatment of autism spectrum disorder (ASD) at the International Society for Autism Research Annual Meeting. The randomized, double-blind, placebo-controlled study consisted of 31 male patients between the ages of 13 and 21 who had been diagnosed with ASD. Participants received either 100 mg of L1-79, 200 mg of L1-79 or placebo, administered three times a day for 28 days. Those in the L1-79 cohorts showed trends in improvement in social functioning and repetitive restrictive behaviors compared to the placebo group, though results did not reach statistical significance. Yamo intends to move forward with a larger study in adolescents and young adults with ASD.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.